'Cll patients' presentation slideshows

542 views • 35 slides

Supplemental Figure 1

Supplemental Figure 1. Zn-BG. A. B. BSO. C. Auranofin. D. carfilzomib. Supplemental Table1: Characteristics of CLL patients in this study; * status unknown. Supplemental Figure 2. Supplemental Figure 3. A. B. Control. 1.0 m M AF, 24 h. CLL, p=.005. 150. NLC, p=ns. CLL-7607.

304 views • 10 slides

Proliferation of CLL Cells After Adoptive Transfer

Proliferation of CLL Cells After Adoptive Transfer. BAFF Promotes CLL Cell Survival. Without BAFF. + BAFF. BCMA-Fc. Anti-BAFF-R. Endo, T, et al. Blood 109 :703-710, 2007. Inhibitors of Nurse-like Cells. Anti-BAFF-R BCMA-Ig. NF-kB Inhibitor IKK-beta Antagonists.

204 views • 7 slides

Prevalence of BTK and PLCG2 Mutations in CLL Patients relapsing under Ibrutinib

68 views • 6 slides